Therapeutic Range of Magnesium Sulfate
Only 67 patients (45.9%) were in the therapeutic range (4.8-8.4 mg/dL). The GDM was significantly associated with non-therapeutic serum magnesium level. (p=0.03) Conclusion: Magnesium sulfate is now the gold standard drug for preventing seizure in pregnant women with severe preeclampsia and eclampsia. The target range for seizure prevention was 4.8 to 8.4 mg/dL. At Chonburi Hospital, only 67 (45.9%) pregnant women were found to have the therapeutic level (4.8-8.4 mg/dL) with magnesium sulfate therapy. In this study, 2.7% of the subjects developed convulsion, this incidence was much more than the other study, 1.9%. Magnesium Sulfate Injection, USP 50% is a sterile, nonpyrogenic, concentrated solution of Magnesium Sulfate heptahydrate in Water for Injection, USP administered by the intravenous (IV) or intramuscular (IM) routes as an electrolyte replenisher or anticonvulsant. Patient response to rise in serum levels: a) Therapeutic: 5-7 mEq/L b) Loss of deep tendon reflexes: 10 mEq/L c) Respiratory failure: 12-15 mEq/L d) Cardiac arrest: 25 mEq/L 3. Calcium gluconate is the antidote for Magnesium Sulfate toxicity. If ordered, administer Calcium Gluconate 10%, IV Push, 10 ml over 3 minutes. Magnesium Sulfate Injection, USP 50% is a sterile, nonpyrogenic, concentrated solution of Magnesium Sulfate heptahydrate in Water for Injection, USP administered by the intravenous (IV) or intramuscular (IM) routes as an electrolyte replenisher or anticonvulsant. Must be diluted before IV use. If you are hospitalized for preeclampsia, you may be prescribed the drug magnesium sulfate. Magnesium sulfate helps prevent the occurrence of seizures in women with severe preeclampsia and decreases seizures in women with eclampsia (seizure activity). Parenteral use of magnesium sulfate in the presence of renal insufficiency may lead to magnesium intoxication. Parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage, and myasthenia gravis. Results: The mean of serum magnesium level was 4.9+1.9 mg/dL. Only 67 patients (45.9%) were in the therapeutic range (4.8-8.4 mg/dL). The GDM was significantly associated with non-therapeutic serum magnesium level. In Pre-eclampsia or Eclampsia. In severe pre-eclampsia or eclampsia, the total initial dose is 10 to 14 g of Magnesium Sulfate. Intravenously, a dose of 4 to 5 g in 250 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP may be infused. The mean serum magnesium level was 4.9+1.9 mg/dL. Seventy nine (54.1%) pregnant women were in the nonthera-peutic level group and only 67 (45.9%) pregnant women were in the therapeutic level group as shown in Table 2. The mean serum creatinine level was 0.82+0.2 mg/dL.
4.8 to 8.4 mg/dl.